Eli Lilly Launches Second Education Program for Medical Students - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eli Lilly Launches Second Education Program for Medical Students


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5
Eli Lilly and Company has developed its second medical student education program, an internship for future physicians. The Lilly Medical Student Intern Program, the second phase of its medical student programs, offers opportunities for medical students between their first and second years to work alongside healthcare professionals in the pharmaceutical industry to gain knowledge and experience in several areas, including preclinical research, clinical trial development, medical affairs, regulatory affairs, bio-ethics, and patient safety.

Six students from Marian University College of Osteopathic Medicine will be the first to participate in the intern program at Lilly’s Indianapolis headquarters. Students will expand their knowledge of the industry by spending time at other facilities, including Covance and Elanco, and participating in team-building activities with other summer interns across the company.

This is the second medical student program launched by Lilly this year. In February, Lilly announced a new partnership with Tulane University School of Medicine to launch the Medical Student Rotation Program, a four-week program for fourth-year medical students. The 10-week Lilly Medical Student Intern Program will run from May through August.

Source: Eli Lilly and Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here